For the Inventor, By the Inventor

Enter inventor name

Menlo Park, CA, United States of America

Thomas J Schall

USPTO Granted Patents = 50 (Patent Applications = 14)

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 8 (Patent Applications = 4)

Average Co-Inventor Count = 4.2

ph-index = 7

Forward Citations = 273(Granted Patents)

Forward Citations (Not Self Cited) = 251(Dec 10, 2025)

Location History:

Meno Park, CA (US) (2006)
Palo Alto, CA (US) (1991 - 2014)
Menlo Park, CA (US) (2003 - 2023)
San Carlos, CA (US) (2006 - 2023)
Mountain View, CA (US) (2020 - 2024)

Company Filing History:

Chemocentryx, Inc.

10 out of 1,829

Schering Corporation

4. 1 out of 5,309

Leland Stanford Junior University

where one patent can have more than one assignee

Years Active: 1991-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Focal Segmental Glomerulosclerosis

Inflammatory Bowel Disease

CCR9 Inhibitors

PD-1 Inhibitors

Chemokine Receptors

Combination Therapy

Tumor Burden Reduction

CX3C Chemokines

Immune Response Modulation

Bis-Aryl Sulfonamides

Chemokine Binding Inhibitors

T-Cell Activation

50 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12194032 - Method of treating focal segmental glomerulosclerosis (2025-01-14),

2. 11883391 - Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies (2024-01-30),

3. 11844790 - Methods of treating hidradenitis suppurativa (2023-12-19),

4. 11744822 - Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors (2023-09-05),

5. 11382915 - Treatment of focal segmental glomerulosclerosis with CCR2 antagonists (2022-07-12),

6. 11324736 - Method of Treating Focal Segmental Glomerulosclerosis (2022-05-10),

7. 11304952 - Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor (2022-04-19),

8. 11045469 - Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodies (2021-06-29),

9. 11020394 - Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C—C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodies (2021-06-01),

10. 10973809 - Method of treating focal segmental glomerulosclerosis (2021-04-13),

11. 10792360 - Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies (2020-10-06),

12. 10758540 - Treatment of focal segmental glomerulosclerosis with CCR2 antagonists (2020-09-01),

13. 10568870 - Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors (2020-02-25),

14. 8642808 - Bis-aryl sulfonamides (2014-02-04),

15. 8637043 - Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof (2014-01-28),

Title: The Innovative Mind of Thomas J Schall

Introduction: Thomas J Schall, a talented inventor based in Menlo Park, CA, has made significant contributions to the field of technology with his creative and groundbreaking ideas.

Latest Patents: Thomas J Schall holds several patents in various technological domains, including artificial intelligence, renewable energy, and medical devices.

Career Highlights: With a career spanning over two decades, Thomas J Schall has worked for renowned tech companies, leading research institutions, and innovative startups, where he has been instrumental in developing cutting-edge technologies.

Collaborations: Throughout his career, Thomas J Schall has collaborated with top engineers, scientists, and researchers from around the world, fostering a culture of innovation and excellence in all his projects.

Conclusion: Thomas J Schall's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors and entrepreneurs.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…